Twist Bioscience (NASDAQ:TWST) (NASDAQ: TWST) is a biotechnology company specializing in the development and manufacturing of synthetic DNA. Founded in 2013 and headquartered in South San Francisco, California, the company leverages a proprietary silicon-based DNA synthesis platform to produce high-quality, high-throughput oligonucleotides and gene fragments. Twist Bioscience’s technology aims to accelerate research and development across life sciences, offering precise control over sequence design and rapid turnaround times for custom DNA products.
The company’s core activities include the synthesis and sale of gene-length DNA, next-generation sequencing (NGS) services, and the provision of custom-designed libraries for applications such as drug discovery, molecular diagnostics, agricultural biotechnology and industrial enzyme development. Twist Bioscience also offers solutions for data storage using DNA as a digital medium, underlining its commitment to innovation at the intersection of biology and technology.
Serving a global customer base, Twist Bioscience maintains operations and distribution channels in North America, Europe and Asia. Its synthetic DNA products support pharmaceutical and academic researchers, as well as synthetic biology companies seeking to design proteins, develop antibodies or engineer metabolic pathways. The company’s robust supply chain and emphasis on automation help ensure consistency and scalability to meet diverse research requirements.
Leadership at Twist Bioscience is led by co-founder and CEO Emily Leproust, Ph.D., whose background in nucleic acid chemistry has guided the company’s technology development and commercialization strategy. The executive team includes seasoned professionals in operations, commercial development and regulatory affairs, positioning the company to address evolving needs in genomic science and biotechnology innovation.
